期刊文献+

急性淋巴细胞白血病阿糖胞苷耐药细胞株的构建及机制研究 被引量:3

Establishment of Cytarabine-resistant Acute Lymphoblastic Leukemia Cell Lines and Its Resistance Mechanism
下载PDF
导出
摘要 目的:构建耐阿糖胞苷(Ara-C)的急性淋巴细胞白血病(ALL)耐药细胞株,并探讨可能耐药机制。方法:低浓度Ara-C持续诱导培养Jurkat和Nalm-6细胞,构建Jurkat/Ara-C和Nalm-6/Ara-C耐药细胞株。CCK-8法检测细胞增殖活力,流式细胞术检测细胞周期分布,实时荧光定量PCR检测多药耐药基因和Ara-C代谢酶m RNA表达水平,免疫印迹法检测细胞周期蛋白表达水平。结果:成功构建了Jurkat/Ara-C和Nalm-6/Ara-C耐药细胞株,耐药指数分别为1 973.908±161.163和7 231.643±1 190.624,耐药细胞株对阿霉素等常用化疗药物无交叉耐药。流式细胞术检测结果显示,Jurkat/Ara-C细胞G_(0)/G_(1)期比例增加(P<0.05),G_(2)/M期减少(P<0.05),而Nalm-6/Ara-C细胞周期分布较Nalm-6细胞无明显改变。实时荧光定量PCR检测发现脱氧胞苷激酶和胞苷脱氨酶在耐药细胞中低表达(P<0.05),MRP在Nalm-6/Ara-C细胞中高表达(P<0.05),MDR1、LRP和BCRP未见明显增加。蛋白免疫印迹检测发现Cyclin B1在耐药细胞中明显低表达(P<0.05),Cyclin D1未见明显改变。结论:低浓度持续诱导法成功构建了ALL耐Ara-C细胞株,其耐药机制可能与脱氧胞苷激酶和Cyclin B1的缺乏有关。 Objective:To establish cytarabine-resistant acute lymphoblastic leukemia(ALL)cell lines and investigate its possible resistant mechanism.Methods:Low-concentration cytarabine(Ara-C)continuously induced and cultured Jurkat and Nalm-6 cells to construct cytarabine-resistant cell lines Jurkat/Ara-C and Nalm-6/Ara-C.The cell viability was detected by CCK-8 assay,and the distribution of cell cycle was detected by flow cytometry.Real-time fluorescence quantitative PCR was used to detect the mRNA expression levels of multidrug resistant gene and Ara-C metabolic enzymes.The expression levels of cyclin were detected by Western blot.Results:Jurkat/Ara-C and Nalm-6/Ara-C drugresistant cell lines were successfully established,the resistance index of which was 1973.908±161.163 and 7231.643±1190.624,respectively.Drug-resistant cell lines had no cross-resistance to commonly used chemotherapeutic drugs,such as doxorubicin.Flow cytometry showed that the ratio of G0/G1 phase in Jurkat/Ara-C cells increased but G2/M phase decreased(P<0.05),while the cell cycle distribution of Nalm-6/Ara-C cells did not change in comparison with Nalm-6 cells.The results of real-time quantitative PCR showed that the expression of deoxycytidine kinase(DCK)and cytidine deaminase(CDA)were significantly down-regulated in drug-resistant cells(P<0.05),MRP was up-regulated in Nalm-6/Ara-C cells(P<0.05),while MDR1,LRP and BCRP did not increase in comparison with parental cells.Western blot analysis revealed that cyclinB1 was significantly under-expressed in drug-resistant cells(P<0.05),while cyclinDl did not change,when compared with parental cells.Conclusion:Cytarabine-resistant ALL cell lines are successfully established by using low concentration continuous induction method,and its drug-resistant mechanism may be related to the deficiencies of DCK and cyclinB 1.
作者 覃祥 刘静 陈曦 钟芳芳 杨友 曾艳 李程 刘文君 QIN Xiang;LIU Jing;CHEN Xi;ZHONG Fang-Fang;YANG You;ZENG Yan;LI Cheng;LIU Wen-Jun(Department of Pediatrics,The Affiliated Hospital of Southwest Medical University,Sichuan Clinical Research Center for Birth Defects,Luzhou 646000,Sichuan Province,China)
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2021年第5期1403-1410,共8页 Journal of Experimental Hematology
基金 四川省应用基础研究项目(NO.2019YJ0690)。
关键词 急性淋巴细胞白血病 阿糖胞苷 耐药 脱氧胞苷激酶 胞苷脱氨酶 CYCLINB1 acute lymphoblastic leukemia cytarabine drug-resistant deoxycytidine kinase cytidine deaminase cyclinB1
  • 相关文献

参考文献11

二级参考文献69

  • 1Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res, 2002, 26:621-629.
  • 2Shen DW, Cardarelli C, Hwang J, et al. Mutiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicines, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem, 1986,261:7762-7770.
  • 3Momparler RL, Laliberte J. Induction of cytidine deaminase in HL-60myeloid leukemic cells by 5-aza-2'-deoxycytidine. Leuk Res, 1990,14:751-754.
  • 4Kawasaki H, Shindou K, Higashigawa M, et al. Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay. Leuk Res, 1996,20 : 677-682.
  • 5Yin B, Kogan SC, Dickins RA, et al. Trp53 loss during in vitro selection contributes to acquired Ara - C resistance in acute myeloid leukemia[J]. Exp Hematol,2006,34(5) :631 - 641
  • 6Cros E,Jordheim L,Durnontet C, et al. Problems related to resistance to cytarabine in acute myeloid leukemia[J ]. Leuk Lymphoma, 2004,45(6) : 1123 - 1132.
  • 7Galrnarini CM, Thomas X,Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients [ J ]. Leuk Res, 2002,26 (7) :621 - 629.
  • 8Sinai C, Vertommen D, Bertrand L, et al. Identification of in vivo phosphorylation sites on human deoxyeytidine kinase. Role of Ser - 74 in the control of enzyme activity [J ]. J Biol Chem, 2006,281 ( 8 ) :4887 - 4893.
  • 9Stammler G, Zintl F, Sauerbrey A, et al. Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia[J]. Anticancer Drugs, 1997,8(5) :517 - 521.
  • 10Shi JY,Shi ZZ,Zhang SJ, et al. Association between single nucleotide polymorphisrns in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients [J ]. Pharmacogenetics, 2004, 14( 11 ) : 759 - 768.

共引文献64

同被引文献27

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部